News articles about Kadmon (NYSE:KDMN) have trended positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kadmon earned a media sentiment score of 0.31 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.7395456004017 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment’s rankings:
- -$0.25 Earnings Per Share Expected for Kadmon Co. (KDMN) This Quarter (americanbankingnews.com)
- Global Ephrin Type B Receptor 4 Market 2018- Eisai Co Ltd, Kadmon Corp LLC, VasGene Therapeutics Inc (satprnews.com)
- Healthcare Stock in Focus: Kadmon Holdings, Inc. (KDMN) (stocksgeeks.com)
- Netanyahu cancels deal with UN to resettle African migrants (kentucky.com)
A number of research firms have commented on KDMN. Zacks Investment Research upgraded shares of Kadmon from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 10th. Piper Jaffray restated a “positive” rating and set a $9.00 price target (up from $7.00) on shares of Kadmon in a research report on Tuesday, February 13th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Kadmon in a research report on Friday, March 9th. Finally, Jefferies Group boosted their target price on shares of Kadmon to $16.00 and gave the stock a “buy” rating in a report on Tuesday, February 13th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $11.45.
Kadmon (NYSE:KDMN) last released its earnings results on Tuesday, March 6th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.12. The business had revenue of $1.50 million during the quarter, compared to the consensus estimate of $3.07 million. During the same quarter in the previous year, the firm earned ($0.50) earnings per share. The firm’s revenue for the quarter was down 65.1% compared to the same quarter last year. analysts predict that Kadmon will post -1.11 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3341238/kadmon-kdmn-receiving-favorable-press-coverage-report-finds.html.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.